Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE: Nursing Roles in Managing Patients With Gastroenteropancreatic Neuroendocrine Tumors.
Clin J Oncol Nurs
; 28(1): 79-87, 2024 Jan 18.
Article
en En
| MEDLINE
| ID: mdl-38252861
ABSTRACT
BACKGROUND:
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a diverse family of cancers that occur within the gastrointestinal tract and pancreas. Peptide receptor radionuclide therapy (PRRT) via 177Lu-DOTATATE is a newer therapeutic option for certain patients with somatostatin receptor-positive GEP-NETs.OBJECTIVES:
This review informs on how oncology nurses treating patients with GEP-NETs receiving PRRT using 177Lu-DOTATATE can facilitate care.METHODS:
Guidance on the monitoring, management, and care of patients undergoing PRRT for GEP-NETs was developed based on published literature and the nursing experience of the authors. A case study is summarized to highlight key concepts.FINDINGS:
Oncology nurses provide assessment, education, direct care, and emotional support when caring for patients with GEP-NETs receiving PRRT with 177Lu-DOTATATE. As the treatment landscape evolves, so too will these roles and responsibilities.Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Compuestos Organometálicos
/
Neoplasias Pancreáticas
/
Neoplasias Gástricas
/
Octreótido
/
Tumores Neuroendocrinos
/
Neoplasias Intestinales
Tipo de estudio:
Guideline
Límite:
Humans
Idioma:
En
Revista:
Clin J Oncol Nurs
/
Clin. j. oncol. nurs
/
Clinical journal of oncology nursing
Asunto de la revista:
ENFERMAGEM
/
NEOPLASIAS
Año:
2024
Tipo del documento:
Article